Abstract
Atherosclerosis is the major cause of cardiovascular morbidity and mortality. A multitude of pro-atherogenic mediators are known liable for the initiation and progression of atherogenic vascular lesions. Only few endogenous molecules are known so far with cardiovascular protective properties, whereas high-density lipoprotein (HDL) is one of the most important. Beside cholesterol efflux, many pleiotropic cell-mediated functions of HDL are known so far. HDL is a spherical particle that contains different proteins and lipids. Especially sphingolipids, like sphingosine-1-phosphate (S1P), has gained great attention. The HDL associated S1P seems to be responsible for many of the pleiotropic effects of HDL by activating special S1P receptors. This review focuses on HDL associated sphingolipids as mediators of known protective pleiotropic effects of HDL and their possible therapeutic relevance.
Keywords: High-density lipoprotein, sphingosine-1-phosphate, pleiotropic effects, sphingosine-1-phosphate receptors, endothelium
Current Pharmaceutical Design
Title: Relevance of Sphingolipids in the Pleiotropic Protective Effects of High-Density Lipoproteins
Volume: 16 Issue: 13
Author(s): Markus Tolle, Mirjam Schuchardt and Markus van der Giet
Affiliation:
Keywords: High-density lipoprotein, sphingosine-1-phosphate, pleiotropic effects, sphingosine-1-phosphate receptors, endothelium
Abstract: Atherosclerosis is the major cause of cardiovascular morbidity and mortality. A multitude of pro-atherogenic mediators are known liable for the initiation and progression of atherogenic vascular lesions. Only few endogenous molecules are known so far with cardiovascular protective properties, whereas high-density lipoprotein (HDL) is one of the most important. Beside cholesterol efflux, many pleiotropic cell-mediated functions of HDL are known so far. HDL is a spherical particle that contains different proteins and lipids. Especially sphingolipids, like sphingosine-1-phosphate (S1P), has gained great attention. The HDL associated S1P seems to be responsible for many of the pleiotropic effects of HDL by activating special S1P receptors. This review focuses on HDL associated sphingolipids as mediators of known protective pleiotropic effects of HDL and their possible therapeutic relevance.
Export Options
About this article
Cite this article as:
Tolle Markus, Schuchardt Mirjam and van der Giet Markus, Relevance of Sphingolipids in the Pleiotropic Protective Effects of High-Density Lipoproteins, Current Pharmaceutical Design 2010; 16 (13) . https://dx.doi.org/10.2174/138161210791050979
DOI https://dx.doi.org/10.2174/138161210791050979 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Myocardial Collagen Network in Hypertensive Heart Disease
Current Hypertension Reviews Oxidative Stress During Myocardial Ischaemia and Heart Failure
Current Pharmaceutical Design MicroRNAs Determining Inflammation as Novel Biomarkers and Potential Therapeutic Targets
Current Medicinal Chemistry L-Type Calcium Channels
Current Pharmaceutical Design Angiotensin Receptor Blockers in Chronic Heart Failure: Clinical Implications and Molecular Mechanisms
Current Cardiology Reviews Toxicology of Trastuzumab: An Insight into Mechanisms of Cardiotoxicity
Current Cancer Drug Targets New Chemotherapeutic Strategies Against Malaria, Leishmaniasis and Trypanosomiases
Current Medicinal Chemistry Combinations Against Combinations: Associations of Anti-HIV 1 Reverse Transcriptase Drugs Challenged by Constellations of Drug Resistance Mutations
Current Drug Metabolism Sirtuins Family- Recent Development as a Drug Target for Aging, Metabolism, and Age Related Diseases
Current Drug Targets Phosphoinositide-3 Kinase Signaling in Cardiac Hypertrophy and Heart Failure
Current Pharmaceutical Design Combating Neurodegenerative Diseases with the Plant Alkaloid Berberine: Molecular Mechanisms and Therapeutic Potential
Current Neuropharmacology Heart Disease in Patients with HIV/AIDS-An Emerging Clinical Problem
Current Cardiology Reviews The Long Way to Objectify Organ Damage Related to Cocaine Abuse: Oxidative Stress is the Main Culprit
Mini-Reviews in Organic Chemistry Patent Selections :
Recent Patents on Cardiovascular Drug Discovery A Practical Guide for the Treatment of Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF)
Current Cardiology Reviews Challenges in Treatment of Inappropriate Sinus Tachycardia
Current Cardiology Reviews Cord Blood as Diagnostic Window for Preeclampsia
Recent Patents on Biomarkers Sarcoidosis in Pregnancy and Postpartum Period
Current Respiratory Medicine Reviews The Fabry Cardiomyopathy - Diagnostic Approach and Current Treatment
Current Pharmaceutical Design Fragmented ECG as a Risk Marker in Cardiovascular Diseases
Current Cardiology Reviews